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dysregulation in non-alcoholic fatty liver
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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. However, its
molecular pathogenesis is incompletely characterized and clinical biomarkers remain scarce. The aims of these
experiments were to identify and characterize liver protein alterations in an animal model of early, diet-related,
liver injury and to assess novel candidate biomarkers in NAFLD patients.
Methods: Liver membrane and cytosolic protein fractions from high fat fed apolipoprotein E knockout (ApoE−/−)
animals were analyzed by quantitative proteomics, utilizing isobaric tags for relative and absolute quantitation
(iTRAQ) combined with nano-liquid chromatography and tandem mass spectrometry (nLC-MS/MS). Differential
protein expression was confirmed independently by immunoblotting and immunohistochemistry in both murine
tissue and biopsies from paediatric NAFLD patients. Candidate biomarkers were analyzed by enzyme-linked
immunosorbent assay in serum from adult NAFLD patients.
Results: Through proteomic profiling, we identified decreased expression of hepatic glyoxalase 1 (GLO1) in a
murine model. GLO1 protein expression was also found altered in tissue biopsies from paediatric NAFLD patients. In
vitro experiments demonstrated that, in response to lipid loading in hepatocytes, GLO1 is first hyperacetylated then
ubiquitinated and degraded, leading to an increase in reactive methylglyoxal. In a cohort of 59 biopsy-confirmed adult
NAFLD patients, increased serum levels of the primary methylglyoxal-derived advanced glycation endproduct,
hydroimidazolone (MG-H1) were significantly correlated with body mass index (r = 0.520, p < 0.0001).
Conclusion: Collectively these results demonstrate the dysregulation of GLO1 in NAFLD and implicate the
acetylation-ubquitination degradation pathway as the functional mechanism. Further investigation of the role
of GLO1 in the molecular pathogenesis of NAFLD is warranted.
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Background
Non-alcoholic fatty liver disease (NAFLD) is increasingly
the most common chronic liver disease in developed
nations, with an estimated global adult prevalence of
25% [1]. Closely associated with obesity, NAFLD is also
an escalating problem both in developing countries [2]
and in children [3, 4]. The term NAFLD encompasses a
range of histopathologies from simple steatosis to non-
alcoholic steatohepatitis (NASH). Whereas steatosis is
considered relatively benign and potentially reversible,
NASH can progress to irreversible fibrosis and cirrhosis,
leading to an increased risk of mortality from liver-related
and cardiovascular-related causes [5]. A natural history
study of NAFLD in children over 20 years demonstrated
that children with NASH can also progress to advanced
fibrosis, cirrhosis and ultimately end-stage liver disease and
death [6]. Due to its increasing burden on health services
worldwide, early screening and diagnosis of NAFLD is
urgently required.
The pathogenesis of NAFLD is clearly multifactorial with
both genetic and environmental factors influencing the de-
velopment and progression of the disease [7]. Current esti-
mates suggest the heritability of NAFLD is around 39% and
several genetic polymorphisms associated with disease risk
have been identified [8, 9]. Risk factors for NAFLD include
obesity, insulin resistance and hyperlipidemia, with a clear
role for diet and physical activity as key modifiable risk fac-
tors [10, 11]. Despite substantial research, the multifactorial
nature of NAFLD has prevented complete characterization
of this disease and the molecular mechanisms that mediate
its pathogenesis. This has contributed to the shortage of ef-
fective molecular biomarkers for early diagnosis and accur-
ate disease staging of NAFLD.
Although tools such as liver function tests, imaging and
complex scoring systems can be useful in decision algo-
rithms for triaging patients for liver biopsy, there are cur-
rently no non-invasive tests that can completely replace
invasive liver biopsy for the detection of NASH [12]. On-
going developments in magnetic resonance-based imaging
techniques are promising, but still require standardization
and validation, and are unlikely to be widely available in the
near future due to cost [13, 14]. In parallel, mass
spectrometry-based proteomic approaches have evolved
considerably in the last decade and offer the power to both
identify disease biomarkers and drug targets while yielding
insight into molecular mechanisms of a clinical condition
[15, 16]. In the context of NAFLD, it is anticipated that a
panel of serum biomarkers, combined with imaging tech-
niques such as transient elastography, will ultimately pro-
vide optimal diagnostic discrimination of NAFLD, and
facilitate the development of NAFLD-specific pharmaco-
therapies [17].
Glyoxalase 1 (GLO1) has been implicated in obesity-
related conditions [18]. It is a critical cytosolic enzyme
involved in the detoxification of reactive dicarbonyls,
principally methylglyoxal (MG). MG is a major source of
advanced glycation end products (AGE) including the
highly reactive MG-derived hydroimidazolones (MG-Hs),
these in turn induce sustained activation of AGE immune
receptors (RAGE) in the circulation. Disruption of the
glyoxalse system and a buildup of MG and MG-Hs is
thought to be central in atherosclerosis and the long-term
vascular complications of diabetes [19]. Animal models
suggest GLO1 activity in the liver is decreased in response
to both high fructose and high fat diets [20] [21], and in-
creased AGEs in liver have been associated with steatosis
severity in NAFLD patients [22]. Despite these associa-
tions, the specific role of GLO1 in the pathogenesis of
NAFLD is unknown.
In this study, we employed quantitative proteomic profil-
ing, utilizing advanced mass spectrometry techniques to
evaluate altered expression patterns of hepatic proteins in a
murine model of atherosclerosis and early liver injury. By
adopting this hypothesis-generating approach, we identified
GLO1 as a candidate biomarker for NAFLD. The results
were validated through a comprehensive range of in vitro
and in vivo experiments involving animal models, HepG2
cells and human hepatic biopsy samples. The underlying
molecular mechanisms and functional pathways were
explored in vitro, and the association of MG-H1 and
sRAGE with liver injury was examined in serum collected
from a cohort of adult patients with histologically con-
firmed NAFLD.
Results
Proteome analysis identifies glyoxalase 1 as a candidate
biomarker for NAFLD
Isobaric tags for relative and absolute quantitation (iTRAQ)
combined with nano-liquid chromatography and tandem
mass spectrometry (nLC-MS/MS) was used to compare
expression profiles of cytosolic and membrane proteins
extracted from the livers of apolipoprotein E knockout
(ApoE−/−) and wild type (WT) mice fed either a normal
chow diet (ND) or a high fat diet (HFD) for a 12-week
period (n = 3/group). The choice of a 12-week time point
in this animal model had been judged as described
below. The experimental workflow is illustrated in Fig.
S1 (Additional file 1: Figure S1).
Proteomic analysis returned > 8000 peptides with a label-
ling efficiency ≥98% for each group (Additional file 1:
Figure S2). Utilizing a protein identification threshold of at
minimum 99% probability and ≥2 unique peptides, Scaffold
calculated a Prophet false discovery rate (FDR) of < 0.05%.
A total of 610 proteins were identified and quantified from
4447 uniquely assigned peptides (Additional files 2 and 3).
Subsequent analyses focused on the 560 (229 cytosolic and
331 membrane) proteins found in all biological replicates
(Fig. 1a). Gene Ontology (GO) analyses confirmed that
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cytoskeletal proteins were detected in the cytosolic fractions
and membrane, ribosomal and endoplasmic reticulum (ER)
proteins were detected in the membrane fraction (Fig. 1b),
thereby verifying the enrichment strategy. 91 cytosolic and
81 membranous proteins were identified as significantly dif-
ferentially expressed (P < 0.05) based on both randomized
permutation and Kruskal-Wallis tests with Benjamini-
Hochberg FDR used for multiple testing corrections
(Additional file 1: Tables S1 and S2). Of 144 unique proteins,
28 proteins were identified in both cytosolic and mem-
brane fractions (Fig. 1c). Although these fractions in-
cluded proteins known to exist in multiple cellular
locations, such as liver fatty acid binding protein
(L-FABP), this result was also attributed to the use of
differential centrifugation as an enrichment strategy, as
opposed to a method of absolute fractionation.
Bioinformatic analyses were done using a variety of open
source tools against several well curated databases. We
a
c
e
b
d
f
g
Fig. 1 iTRAQ-based proteomic analysis of murine liver membrane and cytosolic proteins. a Venn analysis of proteins stringently identified and quantified
by Scaffold_4.8.4 Q+, across biological replicates. Minimum thresholds for protein identification were set at 99% probability and at least 2 unique identified
peptides. Protein probabilities were assigned by the Protein Prophet algorithm [57] and the calculated FDR for protein identification was
< 0.05%. b Annotation of Gene Ontology (GO) category ‘cellular component ‘. c 91 cytosolic and 82 membranous proteins were identified
significantly (P < 0.05) differentially expressed in all biological replicates, based on both randomized permutation and Kruskal-Wallis tests
with Benjamini-Hochberg FDR for multiple testing corrections. 28 proteins were found in extracts from both cellular compartments. d Top functional
annotation clusters, derived from multiple public sources of protein and gene annotation (eg GO, Uniprot, KEGG) utilizing the DAVID [23] knowledgebase,
identified significantly enriched among the differentially expressed proteins. e Pathway topological analysis of the Reactome knowledgebase [25] illustrating
pathway overrepresentation as corrected probability; intensity of scale indicates FDR. The lipid metabolism node is highlighted (in orange with blue writing)
branching from overall metabolism node. f Dysregulated pathways branching from the lipid metabolism node. Box size is proportional to the entities in
the Reactome pathway; the yellow band is proportional to the number of differentially expressed proteins that match against the query dataset; pathways
over-represented are bolded with black text, shaded boxes represent pathways not found enriched. g Connectivity of enriched KEGG knowledgebase [27]
pathways identified by Enrichr [26] analysis.
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used the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [23] for converting protein ac-
cession identifiers to gene symbols and for functional
annotation clustering. DAVID released a completely
rebuilt knowledgebase (version 6.8) in October 2016 over-
coming previous criticism of being outdated [24]. For
functional annotation clustering, DAVID’s algorithim clus-
ters groups across multiple databases with differing bio-
logical focuses and annotation; eg. the Universal Protein
Resource (UniProt), the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and the GO databases). The DAVID
enrichment score is the geometric mean of modified
Fisher Exact tests, where multiple testing correction issues
are considered, associated with the enriched annotation
terms that belong to the group. This analysis identified 33
functional clusters significantly associated with the
proteins identified as dysregulated in this study. Oxidore-
ductase activity, mitochondria and peroxisome, terms in-
dicative of an increased flux in fatty acid metabolism, were
found most significantly enriched (Fig. 1d). Disruption of
lipid, carbohydrates and amino acid metabolism was also
highlighted within the ten most significant functional clus-
ters (Fig. 1d).
Independent analysis of the Reactome pathway knowl-
edgebase [25] identified metabolism as the most overrep-
resented pathway in the dysregulated proteins. Pathway
topological analysis illustrates the corrected probability for
pathway overrepresentation (Fig. 1e; intensity of scale
indicates the Reactome pathway FDR). Significantly overrep-
resented pathways found associated with the differentially
expressed proteins included: lipid, fatty acid, carbohydrate,
tricarboxylic acid cycle (TCA), pyruvate and amino acid
metabolic pathways; along with ketone bodies and biological
oxidation pathways (Fig. 1e). Inspection of pathways
branching from the lipid metabolism node highlighted
in Fig. 1e, shows that peroxisome proliferator-activated
receptor (PPAR) regulated pathways in triglyceride,
fatty acid and ketone metabolism were significantly
overrepresented (bolded boxes, Fig. 1f ). In this repre-
sentation, box size is proportional to the entities associ-
ated with the Reactome pathway, and the yellow band
is proportional to the number of differentially expressed
proteins that match against the query dataset (Fig. 1f).
Specificity is observed here, as some pathways within lipid
metabolism, namely lipid particle organization, sphingo-
lipid metabolism and plasmalogen and wax biosynthesis
were not found enriched (shaded boxes, Fig. 1f). Lastly,
we used the recently updated enrichment analysis tool
Enrichr [26] to examine the KEGG database [27]. In
common with both the DAVID and Reactome analyses,
fatty acid, amino acid, carbohydrate metabolic pathways
were found significantly overrepresented, and connections
between the top ten most significantly overrepresented
pathways were visualized in a network diagram (Fig. 1g).
PPAR signalling was also identified in the Enrichr analysis
as overrepresented, and ranked 11th in the 20 most
significantly overrepresented pathways identified. The dif-
ferentially expressed proteins associated with the top 20
pathways were clustered both by enriched terms and input
protein using the combined score, and visualized as a clus-
tergram (Additional file 1: Figure S3). Collectively, these
bioinformatic analyses infer widespread disturbances in
intermediary metabolism in particular lipid, carbohydrate
and amino acid metabolism.
Among others, L-FABP and fatty acid synthase (FASN)
were also found to be significantly downregulated in the
cytolosic fraction from the livers of ApoE−/− HFD mice
relative to their respective controls (− 0.9, P < 0.0001;
and − 1.15, P < 0.0001, respectively; Additional file 1:
Table S1). Both these proteins have been established as
disrupted in patients with NAFLD [28, 29], suggesting
some sensitivity of our approach to identify candidate
tissue biomarkers relevant to liver injury in human NAFLD.
Of note, the enzyme lactoylglutathione lyase (E.C.4.4.1.5),
commonly known as GLO1, was also identified as differen-
tially expressed (Additional file 1: Figure S4). This was of
interest as we had independently identified GLO1 in pilot
proteomic experiments as downregulated in fatty acid
treated HuH7 cells [30]. Given the association between
GLO1 and obesity and diabetes-related conditions, it repre-
sented an intriguing candidate for further investigation.
ApoE−/− mice develop liver injury in response to a high
cholesterol and high fat diet
In a previous study, Tous and coworkers first demon-
strated that ApoE−/− mice develop hepatic steatosis in
response to 10 weeks on a high-fat (20% palm oil) and
high cholesterol (0.1% w/w cholesterol) diet [31]. Then
in examining pathology in a time course after 5, 10, and
16 weeks on a high palm oil diet, the authors report a
peak in both hepatic steatosis and atheroma burden after
10 weeks on diet, with pathology in 16-week-fed animals
appearing to resolve back to levels observed in 5-week-
fed mice [31]. However, there were no comparisons
drawn to animals fed standard chow at each of the time
points. In light of these results we designed our 16-week
feeding protocol to have 4 equally spaced time points
(after 4, 8, 12 and 16 weeks of diet) with control groups
at each time point, and aimed to explore a time-point
that represented early liver injury.
In examining the proteomic profiles of animals fed
ND or HFD for 12 weeks against the Mouse Genome
Informatics (MGI) Mammalian Phenotype Ontology, the
top 20 most significantly enriched phenotypes were all
indicative of liver injury and/or altered circulating lipid
metabolites (Fig. 2a). The five most significant enriched
ontologies were: ‘hepatic steatosis’, ‘abnormal liver morph-
ology’, ‘enlarged liver’, ‘pale liver’, and ‘liver inflammation’
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(Fig. 2a). Several enzymes involved in methylation reac-
tions clustered highly significantly with liver injury, these
included: methionine adenosyltransferase, glycine N-
methyltransferas and betaine–homocysteine S-methyl
transferase (MAT1a, GNMT and BHMT in Fig. 2a). In
addition, key enzymes associated with fatty acid beta-
oxidation, glycolysis and gluconeogenesis: acyl-CoA oxidase,
aldolase B, and phosphoenolpyruvate carboxykinase 1 (ACO
X1, ALDOB, PCK1 in Fig. 2a) were dysregulated and associ-
ated with liver injury. The iTRAQ experiment detected
APOE as ‘downregulated’ in the liver membrane fraction
from ApoE−/− animals (− 1.15 and − 1.89, P < 0.0051;
Fig. 2a; Additional file 1: Table S2). This serves to il-
lustrate some of the well-known issues with iTRAQ
underestimation and its limitations for precise, as op-
posed to relative, quantitation [32].
Interestingly, beta actin, glyceraldehyde 3-phosphate de-
hydrogenase and liver fatty acid binding protein (ACTB,
GAPDH and FABP1 in Fig. 2a) were all identified as dys-
regulated in our dietary study. We independently observed
a decrease in the detection of L-FABP protein in the livers
of ApoE−/− HFD mice fed for 12 weeks by immunohisto-
chemistry assay (Fig. 2b). When measured quantitatively
by immunoblotting, L-FABP levels in ApoE−/− HFD mice
were fourfold lower relative to those in ApoE−/− ND mice
(P = 0.0441), and sixfold lower relative to those in WT ND
mice (P = 0.0025; Fig. 2C). Because ACTB and GAPDH,
often used as ‘housekeeping’ internal controls, protein ex-
pression was altered by HFD and cytochrome c oxidase
subunit 4 (COXIV) was identified as unregulated (P = 0.92,
Additional file 3), we utilized COXIV for the immunoblot-
ting internal control in downstream experiments. In sum,
these bioinformatic analyses point to liver injury caused
by the disruption of intermediary metabolism, in par-
ticular pathways involved in lipid, carbohydrate and
amino acid metabolism. This is notably accompanied
a b
c
d e
Fig. 2 Hepatic pathology in high fat fed ApoE−/− mice. a Clustergram of gene names for the differentially expressed proteins found significantly
overrepresented in associated MGI Mammalian Phenotype Ontology [61]. Data are shown for top 20 enriched phenotypes, with both phenotypes
and differentially expressed proteins clustered according to the combined statistical score. b Immunohistochemical assay of L-FABP expression in animals fed
diets for 12 weeks. c Immunoblotting and quantification of L-FABP expression normalized to COXIV. Data are mean± SD; n = 3 animals/group. d Liver lipids
were quantified by triacylglycerol assay. e Histology shows that liver sections from ApoE−/− HFD mice exhibit minimal to mild steatosis (arrows) at 12 and
16 weeks. Sections were stained with hematoxylin-eosin; original magnification: 100×
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by dysregulation of proteins commonly thought of as
‘housekeeping’.
While levels of liver triacylglycerol (TAG) were higher
in the ApoE−/− HFD mice at all time points measured,
by 16-weeks these were twofold higher than those in
ApoE−/− ND mice (P = 0.0002, Fig. 2d). In general, the
histological phenotype in the liver was mild. Visualization
of hematoxylin and eosin (H&E) and Masson’s trichrome
stained liver sections showed that ApoE−/− HFD mice de-
veloped only very mild steatosis without visible fibrosis
after 12 weeks (Fig. 2e; and Additional file 1: Figure S5a,
respectively). After 16 weeks, while more pronounced
macrovesicular steatosis was evident, there was no histo-
logical evidence of fibrosis (Fig. 2e; Additional file 1:
Figure S5a). In contrast, the ApoE−/− HFD mice developed
significant aortic sinus plaques after 12 weeks, with a
plaque area that was more than threefold higher compared
to that found in ApoE−/− ND mice (Additional file 1:
Figures S5b & S5c). In comparison, no visible plaques were
detected in WT mice fed either ND or HFD at any of the
time points, and at 16 weeks, the plaque area was >fourfold
higher than that in ApoE−/− ND mice (Additional file 1:
Figures S5b & S5c).
While the liver histology was mild, nonetheless the
changes in liver TAG levels and L-FABP expression, along
with our proteomic data, suggested that the 12-week feed-
ing regime was a valid time point for proteomic analyses
targeted at identifying perturbations in pathways involved
in the early stages of liver injury including NAFLD
pathogenesis.
Expression of glyoxalase 1 was altered in an animal
model of early liver injury
Differential expression of GLO1 in ApoE−/− mice fed a high
fat diet, as detected by iTRAQ (Fig. 3a), was independently
verified by immunohistochemistry. The levels of positive
GLO1 staining in liver sections taken from ApoE−/− ND
mice and WT HFD were higher than those from WT ND
mice; whereas, the staining levels of GLO1 in liver sec-
tions from ApoE−/− HFD mice were considered negligible
(Fig. 3b). Densitometric analysis of immunoblots showed
a twofold increase in the expression of GLO1 protein be-
tween ApoE−/− ND and WT mice, and a fourfold decrease
between that in ApoE−/− HFD and ApoE−/− ND mice
(P = 0.0106; Fig. 3c). Conversely, there was little difference
in the expression level of GLO1 between WT ND and
WT HFD mice, and only a slight decrease in the levels
between ApoE−/− HFD and WT mice.
Lipid loading targeted glyoxalase 1 for proteasomal
degradation with concomitant elevation of intra- and
extracellular methylglyoxal (MG)
Having established a relationship between a high fat diet
and decreased expression of GLO1 in the murine model,
we explored the potential underlying regulatory mechan-
ism in liver cells in vitro using the hepatoma cell line
HepG2. HepG2 cells treated with fatty acids will accu-
mulate lipid droplets and are considered a suitable in
vitro model system for the study of steatosis in human
hepatocytes [33, 34]. Measurement of Nile red staining
showed that treating HepG2 cells with oleic acid (OA)
for 24 h led to a fourfold increase in the level of intracel-
lular lipid (P = 0.0016; Fig. 4a). Immunoblotting revealed
that this increase was accompanied by a significant
decrease in the expression of GLO1 protein (P = 0.0390;
Fig. 4b). Similar treatment with palmitic acid (PA) only
induced a twofold increase in intracellular lipid levels
(P = 0.0738; Fig. 4a) and a slight decrease in GLO1 pro-
tein levels (P = 0.3451; Fig. 4b), thus appearing to relate
to the amount of lipid accumulated in the cells. Import-
antly, a functional effect of the decrease in GLO1 protein
levels was apparent with an increase in the intracellular
levels of the GLO1 substrate, MG in both OA and PA
treated cells (Fig. 4c) compared to vehicle controls, as mea-
sured by the gold standard stable isotopic dilution LC-MS/
MS methodology [35]. This was accompanied by a signifi-
cant increase in the level of MG in the culture media (OA:
P = 0.0176; PA: P = 0.0150, respectively; Fig. 4d). It is diffi-
cult precisely to compare levels/doses of OA and PA be-
tween the in vitro and animal models as the animals were
a b c
Fig. 3 Altered GLO1 expression in animal model of early liver injury. a Median and interquartile range of 10 peptides for GLO1, quantified by iTRAQ-based
proteomics. Whiskers are Tukey’s. b Immunohistochemical assay of GLO1 expression in WT and ApoE−/− animals fed a normal (ND) or high fat diet (HFD)
for 12 weeks. c Immunoblotting and quantification showing GLO1 protein expression relative to COXIV. Data are mean ± SD, n= 3 animals/group
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ad libitum fed a chow diet containing 21% lard, of
which ~ 25% is PA and ~ 45% is OA. Interestingly,
Tous and colleagues used 20% palm oil, which is 48%
SFA with ~ 44% PA & ~ 40% OA and reported a rela-
tively robust liver phenotype after 10 weeks on diet.
However, curiously the pathology appeared to resolve
considerably after 16 weeks on diet, perhaps calling
into question the utility of these model systems for
studying the human NAFLD spectrum.
Functional analyses of our proteomic data had highlighted
the annotation “acetylation” as a post-translational modifica-
tion among the identified proteins. Along with this, global
acetylation-site screening data from rats [36] suggested that
GLO1 might be a target of regulatory post-translational
modification. This was validated by immunoprecipitation
and immunoblotting using an antibody against acetylated
lysines. Both assays provided evidence that the endogenous
GLO1 homodimer, the active form of the enzyme, was acet-
ylated in HepG2 cells. Immunoprecipitates from OA treated
cells exhibited lower levels of the GLO1 homodimer com-
pared to untreated vehicle cells (Fig. 4e). Independent
confirmation was provided by the MS/MS data which iden-
tified the acetylated band as GLO1 (Additional file: Figure
S6). GLO1 is recognized to be both acetylated and ubiquiti-
nated at multiple amino acids, which vary slightly between
human and mouse (human: K-88-ub, K140-ac, K-140-ub,
K148-ac, K-148, K157-ac, K159-ac), and are detailed
within the PhosphoSitePlus manually curated knowledge-
base [37]. As detailed in Hornbeck et al. 2012, these data
come from both journal publications and the CST re-
search group and are based on annotated MS spectra [37].
Although we were able to identify our immunoprecipi-
tated band as GLO1 (Additional file 1: Figure S6), we were
not able to quantify this in our iTRAQ experiment. These
findings suggested that hyperacetylation targeted the ac-
tive form of the GLO1 enzyme for degradation, as seen in
other metabolic enzymes [38]. We examined this hypoth-
esis further by testing for the presence of ubiquitinated
proteins, after applying the proteasomal inhibitor MG-132
prior to immunoprecipitation of GLO1. Immunoblotting
showed a marked increase in ubiquitinated proteins in the
lysates of both vehicle and OA treated cells (Fig. 4g).
e
a b c d
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Fig. 4 Dysregulation of GLO1 in response to lipid loading. HepG2 cells were treated with vehicle, palmitic acid (PA) or oleic acid (OA) for 24 h. a Intracellular
lipid accumulation measured by Nile Red assay, b Immunoblotting and quantification of GLO1 expression relative to TUBA1A, c Cellular methylglyoxal (MG)
levels, and d Medium MG levels from vehicle or fatty acid treated HepG2 cells. Data are mean± SD, n = 3–4 independent experiments. e Acetylation of
endogenous GLO1 immunoprecipitated (IP) from extracts of vehicle or OA treated HepG2 cells with a rabbit anti-GLO1 antibody and immunoblotted (IB) with
rat anti-GLO1 and mouse anti-acetylated lysine. Top panel in red is GLO1 monomer (~21kD) and dimer (~ 45) detected in immunoprecitates of GLO1; less
GLO1 dimer is immunoprecipitated from OA treated cells. Middle panel in green is detection of the GLO1 dimer with an anti-acetyl-lysine anti-
body, with less observed in the GLO1 immunoprecipitates of OA treated cells. Bottom panel is overlay. f Ubiquitination of endogenous GLO1. Top
panel shows ubiquitin detection between 100-150kD in green, in immunoprecipitates of endogenous GLO1; addition of the proteasome inhibitor MG-132
increases GLO1 detection, particularly in OA treated cells. Middle panel shows GLO1 detection in red; very faint banding in the 150 K range only detectable
in the eluates from OA and MG-132 co-treated cells. Bottom panel is overlay
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Furthermore, immunoprecipitation showed that OA
treated cells were clearly polyubiquitinated and that inhib-
ition of the proteasome resulted in a 50% increase in the
GLO1 homodimer (Fig. 4g).
In summary, these data demonstrated that elevated
intracellular lipid levels in hepatic cells induced hypera-
cetylation, followed by ubiquitination and ultimately
degradation of GLO1, with a concomitant accumulation
of extracellular levels of MG.
Adult patients with NAFLD exhibit altered levels of serum
MG-derived hydroimidazolone (MG-H1)
The in vitro data had implied an association between the
degradation of GLO1 protein in hepatocytes and an
increase in extracellular MG in response to high levels
of intracellular lipid. MG is a major source of AGEs;
therefore, to assess the relevance of this finding in hu-
man NAFLD, we investigated the levels of MG-H1, the
most abundant MG-derived AGE, and the soluble recep-
tor for AGEs (sRAGE) in serum collected from a cohort
of biopsy-confirmed adults with NAFLD (Table 1).
Univariate analysis of competitive ELISA data showed that
the MG-H1 residue content of serum protein was signifi-
cantly correlated with both ALT (r= − 0.375; P = − 0.0034)
and ballooning (r = − 0.351; P = 0.0064; Table 2). However,
there was no relationship between MG-H1 residue content
and inflammation or NAFLD activity score (NAS; Table 2).
The strongest correlation was found between the MG-
H1 residue content in serum protein and body mass
index (BMI; r = 0.520, P < 0.0001; Fig. 5a). Furthermore,
when all variables were examined by multiple linear
regression, a model could be fitted whereby BMI pre-
dicted MG-H1 levels. Although univariate analysis had
shown that the median MG-H1 residue content appeared
to be lower in serum protein from patients with NASH
relative to those with simple steatosis, this was not signifi-
cant and there was no difference in the level of sRAGE,
the soluble receptor for AGEs, between patients with
NASH and those with simple steatosis (Additional file 1:
Figure S7). In addition, the correlation analysis found no
associations between sRAGE and any of the tested clinical
features of NAFLD (Additional file 1: Table S3).
Expression of glyoxalase 1 was altered in paediatric
patients with NAFLD
While diagnosis of primary NAFLD in adults may be
confounded by secondary causes (e.g., severe weight loss,
drug, and alcohol consumption), paediatric NAFLD is
considered an excellent model to elucidate the factual
origins of disease [39]. We therefore chose to examine
GLO1 expression by comparing liver biopsies between
nine paediatric patients with NAFLD and three non-
NAFLD controls. Histological review of the nine NAFLD
liver biopsy samples noted various degrees of disease
severity, from mild steatosis with mild or no fibrosis, to
marked steatosis with mild or bridging fibrosis. NAS
scores of the patient samples ranged from 2 to 5 and fi-
brosis was scored F1 in 4, F2 in 1, and F3 in 4 biopsies
(Additional file 1: Table S4); whereas, histological review
of the three control cases revealed minimal and non-
specific changes.
GLO1 expression in the control cases was diffuse
without particular zonality, and the staining was pre-
dominantly cytoplasmic with minimal focal staining sug-
gestive of nuclear expression (Fig. 5b, panels 1 and 3). In
comparison, the staining patterns in the biopsy sections
Table 1 Patient Characteristics1
N 62
Age (years) 47.4 ± 1.36
Male (%) 51
BMI (kg/m2) 36.8 ± 0.96
BMI < 25 (%) 1.6
BMI 25 ≤ x < 30 (%) 17.7
BMI ≥30 (%) 80.6
NAS2 (0–8) 4 (3–5.25)
Steatosis (0–3) 2 (1–3)
Inflammation (0–3) 1 (0–1)
Ballooning (0–2) 1 (0–2)
Fibrosis2 (0–4) 1 (0–1.25)
MG-H1 (pmol/mg protein) 0.902 ± 0.050
sRAGE (pg/ml) 565.6 ± 19.5
ALT (IU) 66.35 ± 6.82
ALP (IU) 85.61 ± 3.76
Bilirubin (μmol/L) 11.79 ± 1.4
Cholesterol (mmol/L) 5.08 ± 0.19
TAG (mmol/L) 2.07 ± 0.23
T2D (%) 19.4
HBP (%) 35.5
1Mean± SEM except as noted; 2median with 25% - 75% percentile. Abbreviations:
BMI, body mass index; NAS, NAFLD activity score; MG-H1, methylglyoxal-
hydroimidazolone 1; sRAGE, soluble receptor for advanced glycation
endproducts; ALT, alanine aminotransferases; ALP, alkaline phosphatase;
TAG, triacylglycerol; T2D, type 2 diabetes; HBP, high blood pressure.
Table 2 Correlation of MG-H1 with clinical features of NAFLD
Variables r P
MG-H1 versus NAS −0.205 0.1203
MG-H1 versus inflammation −0.204 0.1215
MG-H1 versus ballooning −0.351 0.0064
MG-H1 versus ALT −0.375 0.0034
MG-H1 versus BMI 0.520 < 0.0001
Pearson or Spearman correlation was used to analyse the relationship
between variables. Abbreviations: MG-H1, methylglyoxal-hydroimidazolone 1;
NAS, NAFLD activity score; ALT, alanine aminotransferase; BMI, body
mass index
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from the NAFLD cases differed from the control cases,
and numerous hepatocytes, with or without cytoplasmic
changes, showed nuclear staining for GLO1 (Fig. 5b
panels 4–6). In general, non-steatotic non-ballooned hepa-
tocytes retained GLO1 cytoplasmic expression. Whereas
in steatotic hepatocytes, characterized by single large
intracytoplasmic vacuoles, the staining could not be easily
assessed and it appeared to be confined to the peripheral
part of cytoplasm, possibly marginalized by the large stea-
totic droplet. As such, the role of immunohistochemistry
as a tool for investigating cytoplasmic expression of GLO1
may need to be questioned in the context of NAFLD.
Discussion
GLO1 deficiency is recognized as contributing to the
pathogenesis of obesity and diabetic complications.
Metabolic syndrome and obesity have also been linked
to the development and progression of NAFLD. How-
ever, the role of GLO1 in the pathogenesis of NAFLD
has not been established and the involvement of the
glyoxalase system in NAFLD is relatively unexplored.
The biochemical function of GLO1 is the glutathione-
dependent metabolism of the reactive dicarbonyl metabo-
lites, glyoxal and MG, to glycolate and D-lactate respectively,
in order to prevent irreversible protein glycation and the
accumulation of AGEs. A large body of work by Rabbani
and Thornalley over the last two decades has demonstrated
that disturbance of the glyoxalase system plays a central role
in the development of the vascular complications associated
with diabetes and obesity [19]. In the context of diabetes,
hyperglycemia drives an increase in glycolytic flux thereby
increasing MG levels and the formation of AGEs. Parallel
downregulation of GLO1 expression further exacerbates the
formation of MG modified proteins leading to diabetic
nephropathy and neuropathy [40, 41]. It has been claimed
that the downregulation of GLO1 expression is a result of
signalling through the multi-ligand receptor for AGEs
(RAGE) [42]. The AGE Nε-(carboxymethyl)-lysine (CML),
derived from oxidative degradation of fructosamine and
glyoxal has been shown to be increased in fatty liver, and
associated with the severity of steatosis and inflammation
[22]. Glyoxal is a substrate for GLO1 and hence a decrease
in GLO1 activity will contribute to an increase in CML for-
mation. Taken together with previous reports of decreased
hepatic formation of S-D-lactoylglutathione [21] and in-
creased MG-H1 residue content of hepatic plasma protein
[43] in experimental models of NASH, this finding sug-
gested that increased GLO1 proteolysis in the liver in obese
subjects leads to the increased dicarbonyl glycation impli-
cated in NASH. High fructose fed rats were reported to have
decreased GLO1 activity [20], and in a recent metabolomics
study, LDLR−/− mice with high fat diet-induced NASH
showed an 83% decrease in hepatic content of S-D-lactoyl-
glutathione, consistent with a marked decrease in GLO1
activity [21]. Separately, hepatic GLO1 expression was de-
creased in a murine model of hyperhomocysteinemia-
induced fatty liver [44]. In agreement with these reports, we
had independently identified GLO1 as being downregulated
in fatty acid treated HuH7 cells in a pilot proteomic experi-
ment [30] and report here novel data showing alterations in
GLO1 in both animals with early signs of diet-induced liver
injury and paediatric patients with NAFLD.
The regulatory scope of protein acetylation is increasingly
being recognized, largely as a result of advances in prote-
omic technology [38, 45, 46]; and evidence has emerged
that the majority of enzymes involved in intermediary liver
metabolism are dynamically acetylated in response to extra-
cellular nutrient availability [38]. Proteome-wide analyses of
tissue-specific acetylation sites in rat identified the lysine
K148 of GLO1 as highly acetylated in liver, kidney, stomach
and testis [36]; and another study demonstrated that fatty
liver was associated with protein hyperacetylation due to
ba
Fig. 5 Serum MG-H1 levels and altered GLO1 expression in NAFLD patients. a Correlation of MG-H1 with body mass index (BMI) in adult NAFLD patients
(n = 59). b GLO1 immunohistochemistry in a non-NAFLD control case (panels 1,2,3) and in the biopsy specimen of a NAFLD patient (panels 4,5,6). 1: Low
magnification reveals expression of GLO1 in hepatocyte cytoplasm without a particular zonal distribution. 2: Low magnification of a negative
control section without the primary antibody. 3: High magnification shows cytoplasmic staining (asterisks) and focal nuclear staining (arrow) in
hepatocytes. Not all hepatocytes appear to express GLO1 (black triangle). 4: Low magnification reveals bridging fibrosis and severe steatosis with retention
of GLO1 staining in non-steatotic foci (arrows); 5: high magnification shows cytoplasmic staining of GLO1 in non-steatotic hepatocytes (black triangle). A
peripheral staining rim is noted around large steatotic droplet, and expression of GLO1 in marginalised cytoplasm cannot be excluded (arrows). 6: High
magnification reveals nuclear staining (arrows) of GLO1 in many, but not all (triangles), hepatocyte nuclei
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the reduced activity of the mitochondrial SIRT3 dea-
cetylase [47]. Consistent with these data, we found
that GLO1 was acetylated in response to lipid load-
ing in HepG2 cells. Furthermore, our results have
provided novel evidence that hyperacetylation, ubqui-
tinylation and proteasomal targeting of endogenous
GLO1 are involved in the downregulation of GLO1
in response to fatty acids and lipid loading. The
resulting decrease in expression of GLO1 protein led
to an increase in both intra- and extra-cellular levels
of MG. Based on these observations, we have pro-
posed a model for the post-translational regulation of
GLO1 expression in response to shifts in cellular nu-
trient flux (Fig. 6).
MG-derived AGEs have been studied in cirrhosis in
both rats and humans [48, 49], but not in the pathogen-
esis of NAFLD. In humans, a threefold increase in the
level of MG-H1 residue content in plasma protein in
cirrhosis was linked to a decrease in the concentration
of plasma albumin and catabolism [49]. Separately, pa-
tients with NASH were reported to have elevated serum
levels of glyceraldehyde-derived AGE. However, it is un-
clear if serum protein AGE residue content, AGE free
adducts or both contributed to the response, and the
epitope specificity of the antibody used is uncertain [50].
sRAGE has been shown to be significantly lower in
obese children with steatosis as well as lower in adult
NASH patients compared to healthy controls [51, 52].
However, no significant associations were found between
the level of sRAGE and clinical features of NAFLD in
our cohort. This may be attributed to the low number of
participants or differences in the commercial enzyme
immunoassays used.
To our knowledge, there have been no previous reports
of MG-H1 levels in patients with NAFLD. Although uni-
variate analysis had suggested that serum MG-H1 levels in
our cohort of adult patients with NAFLD, were correlated
with ALT and ballooning (hepatocyte injury and fea-
ture of NASH), multiple linear regression indicated
that the MG-H1 residue content of serum was not a
reliable predictor of NAFLD severity, but was signifi-
cantly positively correlated with BMI (P < 0.0001).
This relationship was of interest as it implied that
BMI may be a predictor of MG-H1 residue content
in plasma protein, linking serum MG-H1 levels with
obesity, a major risk factor for NAFLD. This contrasts
with a recent study in subjects without NAFLD that
compared 18 non-obese with 29 obese adults. Al-
though MG levels were found elevated by a ~ 35% in
the obese subjects, there was no difference in MG-H1
levels; a result the authors suggest could relate to de-
creased residence time of albumin from plasma to
interstitial fluid in obesity [18]. However, it has been
observed that plasma protein AGE content may not
be reflective of AGE tissue exposure. In a recent trial
that supplemented obese subjects with a formulation
of dietary bioactives that induce GLO1, both plasma
MG and the endogenous formation of MG-H1 ad-
ducts flux were decreased without a change in plasma
protein MG-H1 [53].
Quantitative analysis of MG-H1 residue content of rat
liver protein suggests relatively high steady-state levels
are maintained in health, 3.3 mmol/mol arginine; there-
fore, GLO1 deficiency in NAFLD may overwhelm the
hepatic capacity for removal of MG-H1-modified pro-
teins contributing to NAFLD progression as suggested
by our results. This possibility merits further research
particularly in light of results from the aforementioned
randomized trial showing that supplementation of
GLO1 inducers (the dietary bioactives trans-resveratrol
and hesperetin) for 8 weeks decreased fasting and post-
prandial glucose levels and increased insulin sensitivity
[53]. Validation of these concepts in NAFLD will require
future prospective intervention studies in larger cohorts,
Fig. 6 Working model for post-translational regulation of GLO1 expression in NAFLD
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ideally using gold-standard LC-MS/MS methodology to
comprehensively assess plasma AGEs and endogenous
flux in NAFLD longitudinally, as previously demon-
strated in type 1 diabetes [54].
Conclusions
In summary, from a hypothesis-generating proteomic
screen of hepatic proteins altered in a murine model,
we identified GLO1 protein as downregulated and
have observed an altered pattern of GLO1 expression
in liver biopsies from paediatric patients with NAFLD.
We also found a strong association between elevated
levels of serum MG-H1 and obesity in adults with
NAFLD. We have observed that GLO1 is hyperacety-
lated, ubiquitinated and degraded in response to an
accumulation of intracellular lipid, with metabolic
consequences for the hepatocyte, providing novel in-
sights into the mechanism underlying the response of
GLO1 to shifts in cellular nutrient content. These
data in total suggest that GLO1 dysregulation may
play a role in NAFLD pathogenesis.
Methods
Clinical samples
In accordance with Helsinki guidelines, informed written
consent was obtained from adult patients and the care-
givers of the paediatric patients participating in this
study. The study was approved by the Tayside Medical
Ethics Committee and the King’s College Hospital NHS
Foundation Trust LEC (REC number 09/H0808/15).
A total of 62 adult patients with biopsy-proven
NAFLD and negative liver screens (negative for viral
hepatitis, autoimmune liver disease, haemochromatosis
and alcoholic liver disease) were included. Subjects were
excluded if their alcohol intakes were > 21 units/week
(male) or > 14 units/week (female). Serum samples were
collected from patients within three months of liver bi-
opsy and then centrifuged at 10,000×g for 10 min before
being stored in 100 μl aliquots at 80 °C within 4 h of
collection.
Liver biopsies from nine paediatric patients with NAFLD
and three control patients were used in this study. Liver bi-
opsy was undertaken as part of routine clinical care and
undertaken by a trained paediatric hepatologist using the
Menghini technique. None of the children with NAFLD
displayed other forms of liver disease, including Wilson’s
disease, viral hepatitis and inborn errors of metabolism.
Due to ethical constraints, the control biopsies included in-
cidental or routine biopsies collected from children with
non-NAFLD diseases. These included a child with auto-
immune pancreatitis, a child exhibiting developmental
delay (underwent biopsy for respiratory chain analysis as
part of metabolic work up), and a child with Hepatitis C.
Control biopsies were histologically confirmed as normal
by an experienced hepato-histopathologist, and liver func-
tion tests were entirely normal.
Animal experiments
All animal care and experimental procedures com-
plied with the Animals (Scientific Procedures) Act
1986, and were approved by the University of Surrey
Animal Ethics Committee. Animals received humane
care and experiments were designed to minimise the
number of animals used. Male mice 6–8 weeks old were
purchased from Charles Rivers, UK (apolipoprotein E
knockout [ApoE−/−], strain B6.129P2-Apoetm1Unc/J on a
C57BL/6 background, and wild type [WT]).
The mice were housed in microisolation cages at con-
stant temperature on a standard 12-h dark/light cycle.
They were fed ad libitum for up to 16 weeks with either
a normal diet (ND; 2.5% fat, 13% protein, 84.5% starch-
based carbohydrate; Special Diets Services, UK) or a
high fat diet (HFD; 21% fat (lard), 0.17% cholesterol, 18%
protein, 60.5% sucrose-based carbohydrate; Teklad, UK).
This atherogenic HFD has been shown to induce NASH
in ApoE−/− mice [31]. The mice were sacrificed at 4, 8,
12 and 16 weeks (n = 3 from each group at each time
point). Blood was collected every four weeks from start
of diet from alternate lateral tail veins of animals under
restraint. Animals were euthanized by intraperitoneal
injection of sodium pentobarbital (200 mg/kg).
On the day of termination, blood was collected from
the hepatic portal vein and the heart and liver were
excised and perfused with phosphate-buffered saline
(PBS) until the majority of the blood was cleared. The
heart and right liver lobe were immersed in phosphate-
buffered formalin for histological examination while the
left liver lobe was snap frozen in liquid nitrogen and
stored at − 80 °C for subsequent use in proteomic-
related studies. Blood samples were centrifuged at
13,000×g for 23 min for plasma collection. Total choles-
terol, HDL cholesterol and TAG measurements were
done using the commercially available enzymatic kits
(Randox, Northern Ireland) and an automated analyzer,
(iLab 650; Instrumentation Laboratory, U.K.) according
to manufacturer’s protocol. The non-HDL cholesterol
(VLDL mainly, and LDL) was determined by subtracting
the HDL cholesterol. In order to measure liver TAG,
liver tissue was homogenized in chloroform/methanol
(2:1, v/v) and lipid was extracted using the Folch method
[55], evaporated under N2 and re-suspended in 2% (v/v)
Triton X-100. TAG concentrations were measured using
a commercial assay (Sigma Aldrich, UK).
Proteomics
Protein extraction
Samples were prepared and labelled with iTRAQ re-
agents as has been described in detail previously [56]. In
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brief, murine liver tissue was homogenised in ice-cold
buffer containing 20 mM Hepes, 1 mM ethylenedi-
aminetetraacetic acid, 300 mM mannitol and protease
inhibitors (HEM buffer), then samples were centrifuged
at 2000×g for 10 min at 4 °C. Supernatants were then
centrifuged at 100,000×g for 30 min. The membrane-
enriched pellet was resuspended in fresh HEM buffer,
while the cytosolic-enriched supernatant was concen-
trated by centrifuging for 1 h at 4000×g through an
Amicon ultra-15 centrifugal filter device (3 kDa MWCO;
Millipore, UK). Sample concentrations were first esti-
mated by the Bradford assay (Sigma, UK). Samples were
desalted thereafter using Zeba columns (7 kDa MWCO;
Pierce, UK) and protein concentration was measured by
BCA assay (Pierce UK).
iTRAQ labelling and nLC-MS/MS
100 μg of cytosolic- and membrane-enriched liver pro-
tein samples from each animal were digested using mass
spectrometry grade trypsin gold (1:10, trypsin:protein ra-
tio; Promega, UK). The resulted peptides were labelled
with iTRAQ reagents (AB Sciex, UK) according to the
manufacturer’s protocol, with 114, 115, 116, and 117
tags corresponding to WT ND, WT HFD, ApoE−/− ND
and ApoE−/− HFD groups (n = 3 biological replicates),
respectively. Labelled peptides were prefractionated, (24
fractions) by isoelectric point using the 3100 OFFGEL
fractionator (Agilent Technologies, UK) following the
manufacturer’s instructions, then dried under vacuum
centrifugation (Concentrator 5301; Eppendorf, UK) and
resuspended in 0.1% (v/v) formic acid. All LC/MS exper-
iments were performed on a 1200 Series HPLC-Chip
interfaced to a 6520 accurate-mass quadrupole time-of-
flight LC/MS (Agilent Technologies, UK). The HPLC-
Chip configuration consisted of a 160 nL enrichment
column and a 150 mm × 75 μm analytical column (Zor-
bax 300SBC18). Mobile phases were buffer A: 0.1%
formic acid in LC/MS grade water, and buffer B: 95%
acetonitrile with 0.1% (v/v) formic acid in LC/MS grade
water. Sample loading onto the enrichment column was
done at 4% B. The gradient used for the analytical
column began at 4% B, raised to 25% B at 21 min, 45% B
at 22.8 min, 65% at 28.8 min, 90% at 29.6 min, main-
tained at 90% B until 30.4 min and then brought back to
4% B at 31.8 min. The column was equilibrated for
10 min before subsequent runs. Samples were loaded at
2.7 μL/min flow rate and eluted at 320 nL/min. The LC/
MS was operated in high resolution (4 GHz) positive ion
mode and the MS source conditions were source
temperature: 325 °C; capillary voltage: 1850 V; fragmen-
tor voltage: 170 V; and drying gas flow rate: 3 L/min.
Data was acquired between m/z 50–3200 at a scan rate
of 1 spectra/s for all samples in the profiling
experiments. In the targeted MS/MS experiment, data
was acquired from 50 to 3200 m/z with an acquisition
rate of 4 spectra/s in MS mode and m/z region 50–3200
with an acquisition rate of 5 spectra/s in MS/MS mode.
Complete system control was achieved using Agilent Mas-
sHunter data acquisition software (B.03.00).
Data analysis
Tandem mass spectra were extracted and charge state
deconvoluted by Mass Hunter version B.03.00 (Agilent
Technologies, USA), while Spectrum Mill and X!Tandem
(The GPM, thegpm.org; version 2007.01.01.1) were used
for protein identification. Deisotoping was not per-
formed. Both Spectrum Mill and X!Tandem were set up
to search a subset of the Swiss-Prot database (Release-
2011_07) (UniProtKB, Swiss-Prot) selected for Mus mus-
culus and assuming digestion with trypsin. The search
was performed with a fragment ion mass tolerance of
50 ppm and a parent ion tolerance of 20 ppm. Oxidation
of methionine, methyl methanethiosulfonate of cysteine
and ABSciexiTRAQ™(0.5 M Triethylammonium bicar-
bonate, 2% SDS, 50 mM Tris2-carboxyethyl-phosphine
hydrochloride and 200 mM MMTS) multiplexed quanti-
tation chemistry of lysine and the n-terminus were spe-
cified in X!Tandem as variable modifications. Scaffold Q
+ (version Scaffold_4.8.4, Proteome Software Inc., USA)
was used for final protein identification and iTRAQ
quantitation. Thresholds of 95% and 99% probability
were used for peptide and protein identifications in
Scaffold respectively. In addition, protein identification
required at least 2 unique identified peptides. Protein
probabilities were assigned by the Protein Prophet algo-
rithm [57] and the calculated FDR for protein identifica-
tion was less than 0.05%. Proteins that contained similar
peptides and could not be differentiated based on MS/
MS analysis alone were grouped to satisfy the principles
of parsimony. Acquired intensities in the experiment
were globally normalized across all acquisition runs. In-
dividual quantitative samples were normalized within
each acquisition run. Intensities for each peptide identi-
fication were normalized within the assigned protein.
The reference channels were normalized to produce a
1:1 fold change. All normalization calculations were per-
formed using averages to multiplicatively normalize data.
Differentially expressed proteins were determined using
both randomised permutation and Kruskal-Wallis tests
with Benjamini-Hochberg FDR for multiple testing cor-
rections. GO annotations were assigned by Scaffold_4.8.4
Q+. The DAVID version 6.8 [23], Reactome pathway ver-
sion 63 [25], and KEGG pathway release 80 [27] knowl-
edgebases were used alongside their, and others tools,
including the enrichment analysis tool Enrichr [26] for
bioinformatics analyses.
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Data repository
The MS proteomics data have been deposited to the
ProteomeXchange Consortium (http://proteomecentral.-
proteomexchange.org) via the PRIDE partner repository
[58] with the dataset identifier PXD001442.
Histopathology and immunohistochemical analyses
Murine liver and heart tissue
Right liver lobes and hearts were fixed in 10% phosphate-
buffered formalin, embedded in fibrowax (BDH, UK), sliced
into sections (4 μm thick) and stained with H&E or Mas-
son’s trichrome. The liver sections were blindly evaluated
and scored by a qualified veterinary pathologist (FJS) for
the degree of non-alcoholic steatohepatitis, as described by
Kleiner [59]. The heart sections were examined by image
analysis software (ImageJ) [60] for quantification of athero-
sclerotic plaques in the proximal aortic sinuses.
Immunolabelling of GLO1 was performed by the avidin-
biotin complex method (ABC Vector Elite; Vector labora-
tories, USA). Briefly, 4-μm thick sections were dewaxed and
rehydrated. Endogenous peroxidase inhibition was carried
out in 3% H2O2 in methanol for 30 min using a Sakura
Tissue Tek DRS 2000 slide autostainer, and antigen retrieval
was performed by microwaving the sections in 0.1 M citric
acid buffer, pH 6.0 (Sigma Aldrich, UK) containing 0.01%
Tween 20 (Fisher Scientific; UK). Slides were cooled to
room temperature (RT) for 30 min, mounted in a Sequenza
Immunostaining Centre (Shandon Scientific, UK) and
washed with Tris buffered saline (TBS; 0.005 M, pH 7.6;
Sigma-Aldrich, UK). Slides were then incubated for 30 min
at RT with 190 μL/slide blocking solution before being incu-
bated with polyclonal rabbit anti-GLO1 primary antibody
(1:100; ab96032-Abcam) for 1 h at RT. The slides were incu-
bated with a biotinylated secondary antibody (1:400; Vector
Laboratories; UK) for 30 min at RT followed by 30 min with
avidin-biotin complex. Labelling was performed using 3,30-
diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich,
UK). Sections were counterstained with Mayer’s haematoxy-
lin, dehydrated and mounted using the slide autostainer.
Images were taken under light microscopy and analysed by
image analysis software (Leica DMLB and Leica QWin V3;
Leica Microsystems GmbH, Germany). Controls were
prepared by labelling serial sections with isotype con-
trol (rabbit IgG).
Human liver biopsy samples
Needle biopsy specimens collected from paediatric pa-
tients were fixed in formalin, embedded in paraffin and
stained for routine histological diagnosis (H&E, reticulin,
diastase PAS, Perls’ and Orcein). Sections (4 μm thick)
were reviewed by a hepatohistopathologist (AQ) blinded
to clinical details. Semi-quantitative analysis was per-
formed using the Brunt/Keliner score method. Qualita-
tive examination of sections for GLO1 immunostaining
(described in detail above) was performed under an
Olympus BX51 light microscope. The staining patterns
were assessed with reference to zonality (distribution in
relation to lobular or acinar zones) and intracellular dis-
tribution (membranous, cytoplasmic or nuclear).
Cell culture
HepG2 cells were obtained from the European Collection
of Cell Cultures and routinely cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5.55 mM
glucose, 10% fetal bovine serum, 1% nonessential amino
acids, 2 mM L-glutamine and 100UI/mL penicillin and
streptomycin (all reagents; Lonza, UK). Cells were seeded
at a density of 30,000/cm2 and cultured for three days
prior to treatment. Palmitic acid (PA; Sigma, UK) and
oleic acid (OA; Sigma, UK) dissolved in dimethyl sulfoxide
(DMSO; Sigma, UK) were complexed with fatty acid free
bovine serum albumin (FAF-BSA; Sigma, UK) for 1 h at
37 °C with mixing every 10 min prior to sterile filtration
and delivery in serum-free media for a 24 h treatment
period; DMSO in FAF-BSA was used as a vehicle control.
Cells were harvested by trypsinization and counted on an
automated cell counter (T20; Biorad, UK). For measure-
ment of intracellular lipid, 500,000 cells were incubated
with 1 μM Nile red (Sigma, UK) in PBS for 10 min at 37 °
C. The cells were centrifuged at 800×g for 10 min, the
supernatant was discarded and the cell pellet was resus-
pended in PBS. Intracellular lipid levels were determined
by measuring fluorescence using a FLUOstar OMEGA
plate reader (BMG LABTECH Ltd., UK) at an excitation
of 485-12 nm with a 520 nm emission filter. MG content
in cells and culture media was measured by stable isotopic
dilution LC-MS/MS [35].
Immunoblotting
Mouse liver and HepG2 cells were lysed in radioimmu-
noprecipitation buffer (Sigma, UK) with a protease in-
hibitor cocktail (Roche, UK). Mouse liver extracts were
taken to a final concentration of 10 mM MgCl2, 10 mM
CaCl2 and DNase treated with 50 units of DNase-I (Pro-
mega, UK) at 37 °C for 2 h. Subsequent heat inactivation
was performed at 65 °C for 30 min. Protein concentration
was determined by bicinchoninic acid (BCA) assay (Pierce,
UK). Protein lysates were resolved by SDS-PAGE and
transferred to polyvinylidene difluoride (PVDF) mem-
branes (Millipore, UK). Membranes were blocked in 5%
(w/v) milk/TBST for 1 h prior to incubation with primary
antibody in TBS-Tween20 (T) for 12–16 h at 4 °C. The
following antibodies were used: anti-L-FABP (1:4000; ab
7847; Abcam, UK); anti-COXIV (1:1000; ab16056; Abcam,
UK) and anti-TUBA1A (1:10,000; ab7291; Abcam, UK).
Anti-GLO1 (1:1000; ab96032; Abcam, UK) was used for
mouse liver samples and anti-GLO1 (1:4000; SAB4200
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193; Sigma UK) was used for HepG2 extracts. The mem-
branes were washed in TBST and incubated with HRP-
conjugated secondary antibodies (Sigma, UK) for 2 h or
fluorescently-tagged antibodies (LICOR Biosciences, UK)
for 1 h. Proteins were either visualized by enhanced chemi-
luminescence (Pierce, UK) and exposed to Hyperfilm™ (GE
Healthcare, UK), or by infrared fluorescence using a
LI-COR Odyssey imaging system (LI-COR Biosciences,
UK). Densitometry was performed using ImageJ [60]
or Image Studio (LI-COR Biosciences, UK) software.
Immunoprecipitation of glyoxalase 1
Immunoprecipitation of GLO1 was performed by crosslink-
ing 50 μl of rabbit polyclonal anti-GLO1 (H00002739-D01;
Abnova, Taiwan) to protein A/G agarose columns (Pierce,
UK) according to the manufacturer’s protocol. Protein
lysates from vehicle and fatty acid-treated cells were pre-
cleared by mixing 1 mg lysate with control agarose resin for
1 h at 4 °C on a rotator, followed by antibody cross-linked
resin overnight at 4 °C. Cleared lysate was eluted according
to the manufacturer’s protocol. The immunoprecipitates
were resolved by 10% SDS-PAGE and visualized by Coo-
massie staining (Sigma, UK). Immunoblotting was carried
out using rat anti-GLO1 (1:4000; SAB4200193; Sigma UK),
mouse anti-acetylated lysine (1:1000; 9681; Cell Signaling
Technology, UK) and mouse anti-ubiquitinated proteins
(1:1000; 04–263, Millipore, UK). For MS confirmation of
GLO1 detection, bands were excised, chopped into 1mm2
pieces and destained in 200 mM NH4HCO3 in 40% (v/v)
acetonitrile. They were washed in 50 mM NH4HCO3,
dehydrated with acetonitrile and subjected to trypsin prote-
olysis overnight at 37 °C using 10 ng/ml trypsin in 50 mM
ammonium bicarbonate. Any peptides remaining in the
excised gel pieces in the supernatant were extracted by son-
ication for 10 min in 50 μL 50:50 acetonitrile:0.1% v/v for-
mic acid. The supernatants were combined, dried and
reconstituted in 3% acetonitrile:97% 0.1% formic acid in
water. Each digested sample was loaded onto a 15 cm×
75μmi.d.PepMap, C18, 3 μm column (LC-Packings) using a
U3000 HPLC system (Thermo, Hemel Hempstead, UK).
HPLC buffers, A and B, consisted of 3% (v/v) aceto-
nitrile:0.1% (v/v) formic acid and 97% (v/v) acetonitrile:0.1%
(v/v) formic acid, respectively. Samples were desalted online
prior to separation using a micro pre-column cartridge
(5 mm× 300μmi.d.). The washing solvent consisted of 3%
(v/v) acetonitrile:0.1% (v/v) trifluoroacetic acid delivered at
a flow rate of 30 μL/min. Peptides were separated over a
gradient of 5% Buffer B to 35% Buffer B over 40 min at a
flow rate of 300 nL/min.
MG-H1 and sRAGE measurements
MG-H1 content in serum samples was measured by
competitive ELISA (Cell Biolabs, UK) and expressed
relative to serum protein content determined by BCA
assay. sRAGE was measured by sandwich ELISA (Cell
Biolabs). ELISA procedures were performed according
the manufacture’s protocols.
Statistical analysis
Experiments were performed in triplicate. Animal and
cell results were expressed as mean ± SEM and were
analysed by two-way or one-way ANOVA with Tukey’s
or Dunnetts post hoc test as appropriate. Human data
were tested for normality using the D’Agostino-Pearson
omnibus test and were analysed by ANOVA/Kruskal
Wallis with Tukey’s/Dunn’s multiple comparison post
hoc test and Spearman’s/Pearson’s correlation, as appro-
priate. For multiple linear regression, the missing values
were imputed using multiple imputation technique.
Model selection procedure was carried out using back-
ward stepwise regression. The model with the lowest
AIC value was considered the best fit. A P-value < 0.05
was considered statistically significant.
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